EP1023076A4 - Use of the p-ten suppressor gene in diagnosis and treatment of cancer - Google Patents

Use of the p-ten suppressor gene in diagnosis and treatment of cancer

Info

Publication number
EP1023076A4
EP1023076A4 EP98908523A EP98908523A EP1023076A4 EP 1023076 A4 EP1023076 A4 EP 1023076A4 EP 98908523 A EP98908523 A EP 98908523A EP 98908523 A EP98908523 A EP 98908523A EP 1023076 A4 EP1023076 A4 EP 1023076A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
cancer
treatment
suppressor gene
suppressor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98908523A
Other languages
German (de)
French (fr)
Other versions
EP1023076A1 (en
Inventor
Ramon E Parsons
Michael H Wigler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cold Spring Harbor Laboratory
Columbia University of New York
Original Assignee
Cold Spring Harbor Laboratory
Columbia University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory, Columbia University of New York filed Critical Cold Spring Harbor Laboratory
Publication of EP1023076A1 publication Critical patent/EP1023076A1/en
Publication of EP1023076A4 publication Critical patent/EP1023076A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
EP98908523A 1997-02-07 1998-02-06 Use of the p-ten suppressor gene in diagnosis and treatment of cancer Withdrawn EP1023076A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3694397P 1997-02-07 1997-02-07
US36943P 1997-02-07
PCT/US1998/002615 WO1998034624A1 (en) 1997-02-07 1998-02-06 Use of the p-ten suppressor gene in diagnosis and treatment of cancer

Publications (2)

Publication Number Publication Date
EP1023076A1 EP1023076A1 (en) 2000-08-02
EP1023076A4 true EP1023076A4 (en) 2001-11-21

Family

ID=21891553

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98908523A Withdrawn EP1023076A4 (en) 1997-02-07 1998-02-06 Use of the p-ten suppressor gene in diagnosis and treatment of cancer

Country Status (4)

Country Link
EP (1) EP1023076A4 (en)
AU (1) AU6653698A (en)
CA (1) CA2280097A1 (en)
WO (1) WO1998034624A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287854B1 (en) 1996-10-22 2001-09-11 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
US6777439B2 (en) * 2000-05-30 2004-08-17 Advanced Research & Technology Institute, Inc. Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
WO2004074459A2 (en) * 2003-02-19 2004-09-02 Georgetown University Pten-deficient cells and their uses
CN109022461B (en) * 2017-06-08 2022-01-14 中山大学附属第一医院 Upstream open reading frame 45aa-uORF nucleotide sequence of PTEN gene and application of encoded polypeptide thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033907A1 (en) * 1997-01-30 1998-08-06 Board Of Regents, The University Of Texas System A tumor suppressor designated ts10q23.3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033907A1 (en) * 1997-01-30 1998-08-06 Board Of Regents, The University Of Texas System A tumor suppressor designated ts10q23.3

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LI D-M ET AL: "TEP1, ENCODED BY A CANDIDATE TUMOR SUPPRESSOR LOCUS, IS A NOVEL PROTEIN TYROSINE PHOSPHATASE REGULATED BY TRANSFORMING GROWTH FACTOR BETA1-", CANCER RESEARCH, vol. 57, 1 June 1997 (1997-06-01), pages 2124 - 2129, XP002066157, ISSN: 0008-5472 *
LIAW DANNY ET AL: "Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.", NATURE GENETICS, vol. 16, no. 1, 16 May 1997 (1997-05-16), pages 64 - 67, XP001024445, ISSN: 1061-4036 *
LO SU HAO ET AL: "Molecular cloning of chick cardiac muscle tensin: Full-length cDNA sequence, expression, and characterization.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 35, 1994, pages 22310 - 22319, XP002178161, ISSN: 0021-9258 *
MYERS ET AL: "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatse", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, 1 August 1997 (1997-08-01), pages 9052 - 9057, XP002088258, ISSN: 0027-8424 *
NELEN M R ET AL: "Localization of the gene for Cowden disease to chromosome 10q22-23.", NATURE GENETICS, vol. 13, no. 1, 1996, pages 114 - 116, XP001024519, ISSN: 1061-4036 *
See also references of WO9834624A1 *

Also Published As

Publication number Publication date
CA2280097A1 (en) 1998-08-13
WO1998034624A1 (en) 1998-08-13
EP1023076A1 (en) 2000-08-02
AU6653698A (en) 1998-08-26

Similar Documents

Publication Publication Date Title
GB9903841D0 (en) Diagnosis and treatment of cancer
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
EP0831904A4 (en) Treatment and diagnosis of prostate cancer
ZA979096B (en) Viral and cancer treatment
HUP0201757A2 (en) Compositoins and methods for the therapy and diagnosis of lung cancer
IL129351A0 (en) Hiv and cancer treatment
HUP0004326A3 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
HK1020259A1 (en) Composition for use in the treatment and prevention of hyperuricemia.
ZA982968B (en) Compositions and methods for the treatment and diagnosis of breast cancer
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
ZA975288B (en) The use of TCET in the prophylaxis and treatment of allergies.
GB9811598D0 (en) Diagnosis and treatment of cancer
HK1063004A1 (en) Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
EP1023076A4 (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
EP0733365A3 (en) Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer
AU2002346049A1 (en) Coactivators in the diagnosis and treatment of breast cancer
GB9812550D0 (en) Tumour therapy and imaging
IL127350A0 (en) Combinations comprising VX478 zidovudine and/or 1592U89 for use in the treatment of HIV
AU5871898A (en) Microparticles and their use in cancer treatment
AU2351699A (en) The human calcium-sensing receptor in the detection and treatment of cancer
EP1001966A4 (en) A senescence gene and its use in the treatment of cancer and other diseases
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer
AU3735100A (en) Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
EP1015559A4 (en) Human regeneration-associated serpin-1 (rasp-1) and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990831

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20011009

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030821